



heartstitch®  
the art of cardiac intervention

**FINAL FOR IMMEDIATE RELEASE**  
[Media Contact](#)

## **HeartStitch® Unveils New Web Portal**

*Beta Release Focuses On Serving Patients and Physicians  
While Showcasing Current And Future Devices*

**Fountain Valley, California—May 23, 2016**—Today HeartStitch® launched a new web portal for both its U.S. and European markets, growing its ability to simultaneously dialogue with the world’s most forward-thinking cardiologists and cardiac surgeons—and their patients. More than a pure marketing platform, [HeartStitch.com](#) was designed from the outset as a true portal that would serve cardiac patients searching for advanced surgical solutions, physicians looking to explore the latest innovations in their field, and both the media and investors, seeking the latest company news. The company’s rapid international growth, and continuous introduction of new devices, made the site’s redesign essential.

Professor Anthony Nobles, CEO of HeartStitch®, commented, “Last year we saw incredible momentum for our company, its products, and successful operations across the globe. 2016 will see that momentum increase as we add to our base of trained cardiologists; those physicians have become increasingly comfortable with the capability our suture based technology; they have continued to publish and present how NobleStitch™ EL protects their patients from the long and short-term complications of ‘umbrella’-type implants; particularly with their experience using NobleStitch EL in a diverse range of patients including younger patients suffering from stroke, severe migraine and chronic fatigue. We needed an intuitive web interface that not only brought physicians and patients together to consider the remarkable benefits that HeartStitch® technology can provide, we also needed to make their success stories available to the world.”

Video content already plays a large role on the portal, and that content will be growing steadily over the weeks and months that follow. Physicians will be able to view actual procedures utilizing a variety of HeartStitch® devices, and cardiac patients considering treatment will hear from others who opted for the company’s latest technology—and see the outcome.

The company’s full line of products are also profiled, including the NobleStitch™ EL and Kwiknot™ accessory, as well as the HeartStitch® TA and HeartStitch® MR. Additionally, a new Investors section will soon provide each shareholder with the encrypted ability to monitor their investments and investor news.



heartstitch®  
the art of cardiac intervention

**FINAL FOR IMMEDIATE RELEASE**  
[Media Contact](#)

Ben Brosch, President of HeartStitch®, commented, “The development of this portal may appear to be common requirement in today’s business world, however for a medical device company it is a significant undertaking. HeartStitch has spent more than six months developing our new portal and now it is more important for us than ever, as interest in our technology—both existing and what we have in development—is exploding. There are lots of questions on a daily basis from physicians, from investors, from patients...and now at least some of these enquiries can be answered on the portal. And there’s more to come, including password-protected areas for physicians and investors. It’s what a company in our position needs, and the time is right.”

### **About HeartStitch®**

**HeartStitch®** Inc. was founded by Prof. Anthony Nobles with the intent of leveraging its technologies in the structural heart marketplace. HeartStitch® is focused on innovative suture-based systems for remotely providing suture repair of structural heart defects and other vascular structures.

The HeartStitch® TA and HeartStitch® MR are FDA cleared for vascular suturing in the United States. HeartStitch® manufactures and markets the NobleStitch™ EL under exclusive license from Nobles Medical technologies II, Inc. NobleStitch™ EL is FDA cleared for vascular suturing in the United States and CE Marked for cardio-vascular suturing and PFO closure in the European Union and the Republic of Kazakhstan, respectively.

**HeartStitch® is a registered trademark of HeartStitch, Inc.**

### **HeartStitch® TA for cardiac suturing and transapical access and closure**

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8348962, 8469975, 8496676, and 8709020.

### **HeartStitch® MR for suturing an anatomical valve**

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8348962, 8469975, 8496676, 8709020, and 8771296.

### **NobleStitch™ EL for PFO closure**

Covered by or for use under U.S. and international patents including one or more of U.S. Patent Nos. 5860990, 6117144, 6245079, 6551331, 6562052, 6733509, 7004952, 7090686, 7803167, 8197497, 8197510, 8246636, 8348962, 8372089, 8469975, 8496676, 8709020, and 9131938.



heartstitch®  
the art of cardiac intervention

**FINAL FOR IMMEDIATE RELEASE**  
[Media Contact](#)

For more on **HeartStitch**® visit [www.HeartStitch.com](http://www.HeartStitch.com)

**For more information, please contact shareholder representatives:**

USA

Dru Dobbs

P. +1 714 427 6348

F. +1 714 427 6343

[ddobbs@HeartStitch.com](mailto:ddobbs@HeartStitch.com)

In Kazakhstan

Kazbek Aubakirov

P. +7 777 5009005

[kaubakirov@HeartStitch.com](mailto:kaubakirov@HeartStitch.com)